Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST

Fig. 1

Volumetric assessment was superior to RECIST at predicting clinical status in this cohort. a Time to radiologic progression by volume. Actuarial median for good clinical outcome = 271 days; median for poor outcome = 156 days; P = 0.012; HR for good vs. poor clinical status = 0.21, P = 0.023. b Time to radiologic progression by RECIST. Actuarial median for good clinical outcome = 271 days; median for poor outcome = 167 days; P = 0.37; HR for good vs. poor clinical status = 0.52, P = 0.38

Back to article page